First Consulting Group Inc.

Philip H. Ockelmann, age 46, joined us as our Corporate Controller in June 1998, and was appointed Vice President, Finance and Controller (Principal Accounting Officer) in June 2000. Prior to joining us, Mr. Ockelmann worked for International Technology Corporation, an environmental management firm, from 1984 through 1998 in various financial positions including Vice President of Finance, Controller and Treasurer.

Thomas A. Watford , age 46, was appointed Chief Operating Officer on March 24, 2006 and Chief Financial Officer on December 12, 2006. He previously served as interim Chief Financial Officer since March 2005 and has been an Executive Vice President since June 2005. Mr. Watford has served in multiple management roles since joining us in May 1997, including Senior Vice President of Shared Services, and as a Vice President in our Health Delivery and Health Plan businesses. Prior to joining FCG, Mr. Watford spent twelve years at Accenture (Andersen Consulting), as an Associate Partner responsible for large client engagements in the health delivery and health plan markets.

Jan L. Blue, age 52, joined us in December 1998 as Director of Human Resources and was appointed to Vice President, Human Resources in October 1999. Prior to joining FCG, she was a healthcare consultant at the Hay Group from December 1996 through December 1998. Prior to that, she served in a variety of senior HR leadership positions at Presbyterian Healthcare System in Dallas (now Texas Healthcare Resources). Ms. Blue is also a Registered Nurse.

Sean McPhillips is a Manager in Integration for First Consulting Group as well as the Founder/Principal of Macro Integration, LLC, a small firm specializing in integration services on the SeeBeyond Product Suite based out of Florence, Kentucky. For the past 13 years, Sean worked in various positions in Healthcare information systems. Such positions include a Principal in the Integration Practice for CTG Healthcare Solutions in Cincinnati, Ohio; Assistant Director of MIS at Phelps Memorial Hospital in Sleepy Hollow, New York; and Senior Project Manager for Stamford Health System in Stamford Connecticut. Sean has been active on the CSOHIMSS Board since 2002 and currently manages the chapter website and edits the quarterly newsletter. He received his CPHIMS Certification in July, 2002 and was elevated to HIMSS Fellow in December 2005.

F. Richard (Dick) Nichol, Ph.D., has spent 38 years in the pharmaceutical, contract clinical research, and biotechnology industries. After receiving M.S. and Ph.D. degrees in Microbiology at Penn State, Nichol began his scientific-business career in 1967 as a research scientist in the Human Virology Research Unit of the Upjohn Co., Kalamazoo, MI. While at Upjohn, Nichol headed teams discovering new antiviral therapies and anti-cancer compounds, and managed field clinical trials of Upjohn products, including Motrin, Xanax, Halcion, Glyburide and immunosuppressive therapies. In 1975, Nichol was co-founder of IBRD, the first phase II and III, III-B and IV Contract Research Organization (CRO) in the U.S. As President and CEO from 1975 to 1995, he led the company to rapid growth and profitability. In 1990, IBRD was sold to a large Japanese pharmaceutical wholesaler, Kuraya Corp., Tokyo. During Nichol's 20-year tenure as President and CEO of IBRD and IBRD Rostrum Global, the company managed over 500 clinical research contracts involving 350 medications. Two strategic acquisitions were completed, and a phase I clinical pharmacology unit was built in New Jersey. At the time of his retirement in 1995, IBRD Rostrum Global had revenues of approximately $45 million, with 437 employees located in 8 countries. IBRD Rostrum Global eventually became part of MDS Pharma, a large international CRO. In 1995, Nichol founded Nichol Clinical Technologies Corp. (NcTc), a pharmaceutical, biotechnology and clinical research-consulting firm. Clients include major U.S. medical schools and teaching hospitals, CROs, investment banking firms, venture capital groups, private equity groups, Fortune 500 firms and IT consultancies, as well as large and small private and public life science companies. He recently served as an advisor to a private equity firm which acquired a Contract Research Organization in the US. Nichol was named President and CEO of CoCensys, a publicly traded neuroscience research company, in 1997. His efforts were directed to rescuing the company from severe financial problems and operating difficulties. Under his leadership, several assets were sold, new licensing deals with large pharmaceutical companies were consummated, right-sizing was implemented, and improved relationships with Wall Street were established. CoCensys was sold to Purdue Pharma in September 1999 for a significant premium to the existing stock price.

Array